Vergnenegre, A.V.: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

51

Corrigendum to “Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer” [Lung Cancer 69S1 (2010) S4–S10]

Nuijten, Mark, Heigener, David F., Bischoff, Helge G., Chouaid, Christos, Vergnenègre, Alain, de Castro Carpeño, Javier, Aultman, Rick, Walzer, Stefan, Siebert, Uwe

Journal:

Year:

2010

Language:

english

File:

PDF, 78 KB

english, 2010

52

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Stanisic, Sanja, Bischoff, Helge G., Heigener, David F., Vergnenègre, Alain, de Castro Carpeño, Javier, Chouaid, Christos, Walzer, Stefan, Mueller, Elvira, Schmidt, Elvira

Journal:

Year:

2010

Language:

english

File:

PDF, 197 KB

english, 2010

53

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer

Nuijten, Mark, Heigener, David F., Bischoff, Helge G., Chouaid, Christos, Vergnenègre, Alain, de Castro Carpeño, Javier, Aultman, Rick, Walzer, Stefan, Siebert, Uwe

Journal:

Year:

2010

Language:

english

File:

PDF, 145 KB

english, 2010

54

38IN CHEMOTHERAPY SELECTION ACCORDING TO CHEMOTHERAPY BIOMARKERS

Rosell, R., Taron, M., Vergnenegre, A., Massuti, B., Carcereny, E., Moran, T., Magri, I., Benlloch, S., Sanchez, J.J., Sanchez Ronco, M.

Journal:

Year:

2011

Language:

english

File:

PDF, 83 KB

english, 2011

55

Septicémie à Erysipelothrix rhusiopathiae

F Touraine, B Melloni, A Vergnenegre, X d'Arco, D Genet, M Mounier, F Bonnaud, J Germouty

Journal:

La Revue de Médecine Interne

Year:

1994

File:

PDF, 214 KB

1994

56

CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER

R Launois, K Le Lay, L Riou França, S Avoinet, N Chemali, A Vergnenegre

Journal:

Value in Health

Year:

2005

Language:

english

File:

PDF, 52 KB

english, 2005

57

PCN29 THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES

M Nuijten, C Chouaid, A Vergnenegre

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 88 KB

english, 2009

58

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

S Walzer, J de Castro Carpeño, A Vergnenegre, C Chouaid, D Heigener, HG Bischoff, R Aultman, U Siebert

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 80 KB

english, 2009

59

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

C Chouaid, A Vergnenegre, M Brunner, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 81 KB

english, 2009

60

PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS

H Rosery, C Castro de, H Bischoff, D Heigener, A Vergnenegre, C Chouaid, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 71 KB

english, 2009

61

PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE) 05–06 STUDY

A Vergnenegre, R Corre, H Berard, D Paillotin, C Dujon, G Robinet, J Crequit, S Bota, P Thomas, C Chouaid

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 72 KB

english, 2009

62

PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY

H Rosery, HG Bischoff, A Vergnenegre, C Chouaid, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 80 KB

english, 2009

63

PCN13: MANAGEMENT OF LUNG CANCER IN FRANCE

C Schmitt, A Vergnenegre, MP Schuller-Lebeau, M Frappe, O Bouin

Journal:

Value in Health

Year:

2000

Language:

english

File:

PDF, 52 KB

english, 2000

64

PCN9 OBSERVATIONAL STUDY OF PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) TREATED BY ERLOTINIB: CLINICAL PRACTICES AND MAIN OUTCOMES IN FRANCE

A Vergnenegre, I Monnet, C Chouaid, J Hureaux, J Mazières, G Quéré, JN Lombard, I Cumin, S Abdiche, Ejnaini C Nocent, C Decroisette

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 76 KB

english, 2010

65

PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED + CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

K Berenson, C Chouaid, A Vergnenegre, S Sherman, S Walzer

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 78 KB

english, 2010

66

PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Y Yi, C Chouaid, A Vergnenegre, HG Bischoff, G Bergman, S Walzer, Z Philips

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 99 KB

english, 2010

67

PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)

C Chouaid, H Lecaer, J Crequit, I Monnet, S Chouabe, C Locher, D Paillotin, JB Auliac, P Thomas, A Vergnenegre

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 79 KB

english, 2010

68

PCN110 RESOURCE UTILIZATION AND DIAGNOSTIC APPROACHES IN NON-SMALL-CELL LUNG CANCER (NSCLC) ACROSS EUROPE: EPICLIN-LUNG STUDY

A Vergnenegre, G Cruciani, M Thomas, E Guallar, E Medina, A Carrato

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 76 KB

english, 2010

69

PCN133 EPICLIN-LUNG STUDY: NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENT QUALITY OF LIFE AND HEALTH-STATE ASSESSMENT

M Thomas, G Cruciani, A Vergnenegre, E Guallar, E Medina, A Carrato

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 78 KB

english, 2010

70

PCN104 SOCIETAL COST SAVINGS IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

S Stanisic, A Vergnenegre, C Chouaid, E Mueller, S Walzer

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 70 KB

english, 2010

71

PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY

A. Vergnenegre, D.F. Heigener, H.G. Bischoff, C. Chouaid, G. Taylor-Stokes, A. Roughley, S. Walzer

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 57 KB

english, 2011

72

PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

H.G. Bischoff, C. Chouaid, A. Vergnenegre, D.F. Heigener, G. Taylor-Stokes, A. Roughley, S. Walzer

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 58 KB

english, 2011

73

PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

L. Heron, J. De Castro Carpeño, C. Chouaid, A. Vergnenègre, H.G. Bischoff, S. Walzer

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 74 KB

english, 2011

74

PCN94 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING: BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY

C. Chouaid, H.G. Bischoff, A. Vergnenegre, D.F. Heigener, G. Taylor-Stokes, A. Roughley, S. Walzer

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 58 KB

english, 2011

75

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer

Vergnenègre, A., Daniel, C., Léna, H., Fournel, P., Kleisbauer, J.P., Caer, H. Le, Letreut, J., Paillotin, D., Pérol, M., Bouchaert, E., Preux, P.M., Robinet, G.

Journal:

Year:

2005

Language:

english

File:

PDF, 174 KB

english, 2005

76

Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer

Thomas, P., Robinet, G., Gouva, S., Fournel, P., Léna, H., Le Caer, H., Perol, M., Berard, H., Bombaron, P., Vergnenegre, A., Kleisbauer, J.P.

Journal:

Year:

2006

Language:

english

File:

PDF, 204 KB

english, 2006

77

Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study

Vergnenègre, A., Monnet, I., Chouaïd, C., Hureaux, J., Mazières, J., Quéré, G., Lombard, J.N., Cumin, I., Abdiche, S., Ejnaini, C. Nocent, Bonnabau, H., Decroisette, Ch.

Journal:

Year:

2011

Language:

english

File:

PDF, 274 KB

english, 2011

78

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Banz, Kurt, Bischoff, Helge, Brunner, Matthias, Chouaid, Christos, de Castro Carpeño, Javier, de Marinis, Filippo, Grossi, Francesco, Vergnenègre, Alain, Walzer, Stefan

Journal:

Year:

2011

Language:

english

File:

PDF, 232 KB

english, 2011

79

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer

Nuijten, Mark J.C., de Castro Carpeño, Javier, Chouaid, Christos, Vergnenègre, Alain, Grossi, Francesco, Bischoff, Helge, Heigener, David, Walzer, Stefan

Journal:

Year:

2012

Language:

english

File:

PDF, 375 KB

english, 2012

80

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

LeCaer, H., Greillier, L., Corre, R., Jullian, H., Crequit, J., Falchero, L., Dujon, C., Berard, H., Vergnenegre, A., Chouaid, C.

Journal:

Year:

2012

Language:

english

File:

PDF, 268 KB

english, 2012

81

Traitement des fractures comminutives de l’extrémité distale du radius du sujet âgé par prothèse de resurfaçage

G. Vergnenegre, P.S. Marcheix, V. Vacquerie, J.-P. Arnaud, J.-L. Charissoux, C. Mabit

Journal:

Chirurgie de la Main

Year:

2012

Language:

french

File:

PDF, 62 KB

french, 2012

82

PCN3 ECONOMIC IMPACT OF SECOND- ANDTHIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER:A FRENCH OBSERVATIONAL STUDY

C Chouaid, A Vergnenegre, A Moser, C Coudray-Omnes

Journal:

Value in Health

Year:

2007

Language:

english

File:

PDF, 74 KB

english, 2007

83

PCN23 A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

K Le Lay, L Riou-França, S Avoinet, N Chemali, A Vergnenègre, R Launois

Journal:

Value in Health

Year:

2004

Language:

english

File:

PDF, 66 KB

english, 2004

84

PRS2 COST OF CHRONIC BRONCHITIS (CB) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN FRANCE: THE BRONCHECO STUDY

G Huchon, A Crochard, A Vergnenegre, X Lenne, C Chidiac, F Neukirch, I Boucot

Journal:

Value in Health

Year:

2004

Language:

english

File:

PDF, 64 KB

english, 2004

85

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

Chouaid Christos, Le Caer Hervé, Locher Chrystelle, Dujon Cecile, Thomas Pascal, Auliac Jean Bernard, Monnet Isabelle, Vergnenegre Alain

Journal:

Year:

2012

Language:

english

File:

PDF, 569 KB

english, 2012

86

The Cost of Lung Cancer Management in France from the Payor’s Perspective

Dr Alain Vergnenègre, Laurent Molinier…

Journal:

Disease Management & Health Outcomes

Year:

2006

Language:

english

File:

PDF, 160 KB

english, 2006

87

Le financeur, la T2A, le médecin, le patient : l’exemple de la cancérologie thoracique

Vergnenègre, A.

Journal:

Revue des Maladies Respiratoires

Year:

2007

Language:

french

File:

PDF, 137 KB

french, 2007

88

Analyse économique de l’administration d’une chimiothérapie en hospitalisation à domicile (HAD) comparée à l’hospitalisation de jour dans les cancers bronchopulmonaires non à petites cellules de stade IV

Vergnenègre, A., Decroisette, C., Vincent, F., Dalmay, F., Melloni, B., Bonnaud, F., Eichler, B.

Journal:

Revue des Maladies Respiratoires

Year:

2006

File:

PDF, 150 KB

2006

89

Le coût du traitement de la BPCO au Danemark est de 256 millions d’euros

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2007

Language:

french

File:

PDF, 78 KB

french, 2007

90

Forthcoming meetings

Preux, P.M., Odermatt, P., Perna, A., Marin, B., Vergnenègre, A.

Journal:

Progress in Organic Coatings (Elsevier)

Year:

1986

Language:

english

File:

PDF, 130 KB

english, 1986

91

En France, comme dans beaucoup d’autres pays (Australie, Suisse, Canada, Angleterre, Chine, USA) l’utilisation précoce de budésonide, dans les asthmes modérés, réduit les coûts mais le rapport coût-efficacité, du point de vue de la société, n’est pas favorable, alors qu’il l’est dans certains pays (Australie, Canada, Suisse)

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2005

Language:

french

File:

PDF, 103 KB

french, 2005

92

En France, 3,5 % de dépenses de santé sont consacrées à la BPCO

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2005

Language:

french

File:

PDF, 128 KB

french, 2005

93

L’utilisation d’anti-IgE est coût-efficace (sous certaines conditions) dans le traitement de l’asthme

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2007

Language:

french

File:

PDF, 81 KB

french, 2007

94

Impact de l’évaluation gériatrique sur la décision de traitement en oncologie thoracique

Aliamus, V., Adam, C., Druet-Cabanac, M., Dantoine, T., Vergnenegre, A.

Journal:

Revue des Maladies Respiratoires

Year:

2011

File:

PDF, 304 KB

2011

95

Le propionate de fluticasone est coût-efficace dans le traitement de la BPCO

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2007

Language:

french

File:

PDF, 79 KB

french, 2007

96

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

Chouaid, C., Le Caer, H., Corre, R., Crequit, J., Jullian, H., Falchero, L., Dujon, C., Vergnenegre, A.

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 63 KB

english, 2011

97

Plating of sintered Fe parts and diffusion annealing of coatings

Chouaid, C., Le Caer, H., Corre, R., Crequit, J., Jullian, H., Falchero, L., Dujon, C., Vergnenegre, A.

Journal:

Metal Powder Report

Year:

1990

Language:

english

File:

PDF, 105 KB

english, 1990

98

Les soins de support dans les cancers bronchopulmonaires (CBP)

Vergnenègre, A., Terrier, G.

Journal:

Revue des Maladies Respiratoires

Year:

2013

Language:

french

File:

PDF, 304 KB

french, 2013

99

Les exacerbations de BPCO sont associées à une faible consommation de resources en médecine ambulatoire

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2007

Language:

french

File:

PDF, 73 KB

french, 2007

100

Évaluation économique de l’immunothérapie sublinguale comparée aux traitements symptomatiques des allergies respiratoires dues au pollen chez les adultes

Vergnenègre, A., Chouaïd, C.

Journal:

Revue des Maladies Respiratoires

Year:

2007

Language:

french

File:

PDF, 71 KB

french, 2007